Jang Ho Lee, Eun Young Kim, Cheol-Kyu Park, Shin Yup Lee, Min ki Lee, Seong-Hoon Yoon, Jeong Eun Lee, Sang Hoon Lee, Seung Joon Kim, Sung Yong Lee, Jun Hyeok Lim, Tae-Won Jang, Seung Hun Jang, Kye Young Lee, Seung Hyeun Lee, Sei Hoon Yang, Dong Won Park, Chan Kwon Park, Hye Seon Kang, Chang Dong Yeo, Chang-Min Choi, Jae Cheol Lee
Cancer Res Treat. 2023;55(1):112-122. Published online July 19, 2022
Purpose Although osimertinib is the standard-of-care treatment of epidermal growth factor receptor (EGFR) T790M mutation–positive non–small cell lung cancer, real-world evidence on the efficacy of osimertinib is not enough to reflect the complexity of the entire course of treatment. Herein, we report on the use of osimertinib in patients with EGFR T790M mutation–positive non–small cell lung cancer who had previously received EGFR tyrosine kinase inhibitor (TKI) treatment in Korea.
Materials and Methods Patients with confirmed EGFR T790M after disease progression of prior EGFR-TKI were enrolled and administered osimertinib 80 mg daily. The primary effectiveness outcome was progression-free survival, with time-to-treatment discontinuation, treatment and adverse effects leading to treatment discontinuation, and overall survival being the secondary endpoints.
Results A total of 558 individuals were enrolled, and 55.2% had investigator-assessed responses. The median progression-free survival was 14.2 months (95% confidence interval [CI], 13.0 to 16.4), and the median time-to-treatment discontinuation was 15.0 months (95% CI, 14.1 to 15.9). The median overall survival was 36.7 months (95% CI, 30.9 to not reached). The benefit with osimertinib was consistent regardless of the age, sex, smoking history, and primary EGFR mutation subtype. However, hepatic metastases at the time of diagnosis, the presence of plasma EGFR T790M, and the shorter duration of prior EGFR-TKI treatment were poor predictors of osimertinib treatment. Ten patients (1.8%), including three with pneumonitis, had to discontinue osimertinib due to severe adverse effects.
Conclusion Osimertinib demonstrated its clinical effectiveness and survival benefit for EGFR T790M mutation–positive in Korean patients with no new safety signals.
Citations
Citations to this article as recorded by
The importance of re-biopsy in the era of molecular therapy for lung cancer Nensi Lalic, Daliborka Bursac, Marko Bojovic, Marko Nemet, Ivan Ergelasev Srpski arhiv za celokupno lekarstvo.2024; 152(3-4): 209. CrossRef
Detection of EGFR exon 20 insertion mutations in non-small cell lung cancer: implications for consistent nomenclature in precision medicine Jieun Park, Boram Lee, Ji-Young Song, Minjung Sung, Mi Jeong Kwon, Chae Rin Kim, Sangjin Lee, Young Kee Shin, Yoon-La Choi Pathology.2024; 56(5): 653. CrossRef
Real‐world study of lazertinib as second‐line or greater treatment in advanced non‐small cell lung cancer Jeong Uk Lim, Kyuhwan Kim, Kyu Yean Kim, Hye Seon Kang, Ah. Young Shin, Chang Dong Yeo, Sung Kyoung Kim, Chan Kwon Park, Sang Haak Lee, Seung Joon Kim Thoracic Cancer.2024; 15(19): 1513. CrossRef
Comparative effectiveness of lazertinib in patients with EGFR T790M-positive non-small-cell lung cancer using a real-world external control Ha-Lim Jeon, Meesong Kwak, Sohee Kim, Hye-Yeon Yu, Ju-Young Shin, Hyun Ae Jung Scientific Reports.2024;[Epub] CrossRef
A Randomized, Multi-Center, Open Label Study to Compare the Safety and Efficacy between Afatinib Monotherapy and Combination Therapy with HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients with EGFR Mutations Eunbin Kwag, Soo-Dam Kim, Seong-Hoon Shin, Chulho Oak, So-Jung Park, Jun-Yong Choi, Seong Hoon Yoon, In-Cheol Kang, Mi-Kyung Jeong, Hyun Woo Lee, Sun-Hwi Bang, Ji Woong Son, Sanghun Lee, Seung Joon Kim, Hwa-Seung Yoo Integrative Cancer Therapies.2024;[Epub] CrossRef
Clinical utility of repeated rebiopsy for EGFR T790M mutation detection in non-small cell lung cancer Eun Hye Lee, Se Hyun Kwak, Kyeong Yeon Kim, Chi Young Kim, Sang Hoon Lee, Seok-Jae Heo, Yoon Soo Chang, Eun Young Kim Frontiers in Oncology.2024;[Epub] CrossRef
Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study Qing Zhou, He-Long Zhang, Li-Yan Jiang, Yuan-Kai Shi, Yuan Chen, Jin-Ming Yu, Cai-Cun Zhou, Yong He, Yan-Ping Hu, Zong-An Liang, Yue-Yin Pan, Wen-Lei Zhuo, Yong Song, Gang Wu, Gong-Yan Chen, You Lu, Cui-Ying Zhang, Yi-Ping Zhang, Ying Cheng, Shun Lu, Chan Journal of Cancer Research and Clinical Oncology.2023; 149(12): 10771. CrossRef
Purpose Direct sequencing (DS) is the standard method for detection of epidermal growth factor receptor (EGFR) gene mutation in non-small cell lung cancer (NSCLC); however, low detection sensitivity is a problem. The aim of this study is to demonstrate higher detection rate of EGFR gene mutation with peptide nucleic acid (PNA) clamping compared with DS. Materials and Methods This is a single arm, prospective study for patients with stage IIIB/IV or relapsed NSCLC. Using tumor DNA from 138 patients, both DS and PNA clamping for EGFR gene in exon 18, 19, 20, and 21 were performed. Discrepant results between the two methods were verified using Cobas and a mutant enrichment based next generation sequencing (NGS). Patients with activating mutations were treated with EGFR tyrosine kinase inhibitor (EGFR-TKI, gefitinib, or erlotinib) as first line treatment.
Results Of 138 paired test sets, 24 (17.4%) and 45 (32.6%) cases with activating mutations were detected by DS and PNA clamping, respectively. The difference of detection rate between the two methods was 15.2% (95% confidence interval, 8.7% to 17.8%; p < 0.001). Between the two methods, 25 cases showed discrepant results (n=23, PNA+/DS–; n=2, PNA–/DS+). Mutations were confirmed by Cobas or NGS in 22 of 23 PNA+/DS– cases. The response rates to EGFR-TKI were 72.2% in the PNA+/DS+ group and 85.0% in the PNA+/DS– group. Conclusion PNA clamping showed a significantly higher detection rate of EGFR gene mutation compared with DS. Higher sensitivity of PNA clamping was not compromised by the loss of predictive power of response to EGFR-TKI.
Citations
Citations to this article as recorded by
Highly Sensitive Enrichment of Low-Frequency Variants by Hairpin Competition Amplification Zhaocheng Liu, Rui Zhang, Xixi Jiang, Li Ji, Ping Sun, Yong Ji, Yu Zhang, Yan Ding, Koukou Li, Zhening Pu, Fengsheng Zhou, Jian Zou Analytical Chemistry.2023; 95(32): 12015. CrossRef
Peptide Nucleic Acids: Recent Developments in the Synthesis and Backbone Modifications Gurpreet Singh, Vikramdeep Monga Bioorganic Chemistry.2023; 141: 106860. CrossRef
Genetic Alterations and Risk Factors for Recurrence in Patients with Non-Small Cell Lung Cancer Who Underwent Complete Surgical Resection Hwa Park, Yoo Choi, Ju-Sik Yun, Sang-Yun Song, Kook-Joo Na, Joon Yoon, Chang-Seok Yoon, Hyung-Joo Oh, Young-Chul Kim, In-Jae Oh Cancers.2023; 15(23): 5679. CrossRef
Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment Hayoung Choi, Jae‐Kyeong Lee, Hyung‐Joo Oh, Min‐Seok Kim, Bo Gun Kho, Cheol Kyu Park, In‐Jae Oh, Young‐Chul Kim Thoracic Cancer.2021; 12(10): 1598. CrossRef
Bronchial brushing cytology is comparable to bronchial biopsy for epidermal growth factor receptor mutation test in non-small cell lung cancer Joo-Yeon Koo, Nah-Ihm Kim, Taebum Lee, Yoo-Duk Choi Cytojournal.2020; 17: 16. CrossRef
Potential applications of peptide nucleic acid in biomedical domain Kshitij RB Singh, Parikipandla Sridevi, Ravindra Pratap Singh Engineering Reports.2020;[Epub] CrossRef
Prognostic value of quantitative measurement of EGFR mutation using peptide nucleic acid clamping in advanced EGFR mutant non‐small cell lung cancer patients Insu Kim, Jung Seop Eom, Eun Jung Jo, Jeongha Mok.Ki Uk, Kwangha Lee, Ki Uk Kim, Hye‐Kyung Park, Min Ki Lee, Mi‐Hyun Kim Thoracic Cancer.2019; 10(7): 1561. CrossRef
Sensitive detection of low-abundance in-frame deletions in EGFR exon 19 using novel wild-type blockers in real-time PCR Xiao-Dong Ren, Ding-Yuan Liu, Hai-Qin Guo, Liu Wang, Na Zhao, Ning Su, Kun Wei, Sai Ren, Xue-Mei Qu, Xiao-Tian Dai, Qing Huang Scientific Reports.2019;[Epub] CrossRef
Peptide Nucleic Acid Clamping and Direct Sequencing in the Detection of Oncogenic Alterations in Lung Cancer: Systematic Review and Meta-Analysis Jae-Uk Song, Jonghoo Lee Yonsei Medical Journal.2018; 59(2): 211. CrossRef
Comparative analysis of Adam33 mutations in murine lung cancer cell lines by droplet digital PCR, real-time PCR and Insight Onco™ NGS Soo-Jin Kim, Eunhee Kim, Kyung-Taek Rim Molecular & Cellular Toxicology.2018; 14(2): 221. CrossRef
Feasibility of re‐biopsy and EGFR mutation analysis in patients with non‐small cell lung cancer Tae‐Ok Kim, In‐Jae Oh, Bo Gun Kho, Ha Young Park, Jin Sun Chang, Cheol‐Kyu Park, Hong‐Joon Shin, Jung‐Hwan Lim, Yong‐Soo Kwon, Yu‐Il Kim, Sung‐Chul Lim, Young‐Chul Kim, Yoo‐Duk Choi Thoracic Cancer.2018; 9(7): 856. CrossRef
Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma In-Jae Oh, Jae Young Hur, Cheol-Kyu Park, Young-Chul Kim, Seung Joon Kim, Min Ki Lee, Hee Joung Kim, Kye Young Lee, Jae Cheol Lee, Chang-Min Choi Clinical Lung Cancer.2018; 19(5): e775. CrossRef
Genetic Biomarkers and Their Applications to Prevent Occupational Diseases: A Literature Review Kyung-Taek Rim Toxicology and Environmental Health Sciences.2018; 10(3): 147. CrossRef
Molecular masquerading of rare EGFR L858M/L861R mutations as common L858R/L861Q mutations by PNA clamping assay Ji Hyung Hong, Seung-Hyun Jung, Min Sung Kim, Sug Hyung Lee, Yeun-Jun Chung Pathology.2017; 49(4): 453. CrossRef
Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast Cancer Aeri Kim, Min Hye Jang, Soo Jung Lee, Young Kyung Bae Journal of Breast Cancer.2017; 20(2): 150. CrossRef
Peptide nucleic acids: Advanced tools for biomedical applications Anjali Gupta, Anuradha Mishra, Nidhi Puri Journal of Biotechnology.2017; 259: 148. CrossRef
Non-invasive quantification of cell-free DNA mutations in plasma during lung tumor progression in mice Soo-Jin Kim, Eunhee Kim, Kyung-Taek Rim Cancer Biomarkers.2017; 20(4): 477. CrossRef
Peptide Nucleic Acid-Based Biosensors for Cancer Diagnosis Roberta D’Agata, Maria Giuffrida, Giuseppe Spoto Molecules.2017; 22(11): 1951. CrossRef
Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing Mi-Young Park, Min Hee Jung, Eun Young Eo, Seokjoong Kim, Sang Hoon Lee, Yeon Joo Lee, Jong Sun Park, Young Jae Cho, Jin Haeng Chung, Cheol Hyeon Kim, Ho Il Yoon, Jae Ho Lee, Choon-Taek Lee Oncotarget.2017; 8(22): 36331. CrossRef
Application of Peptide Nucleic Acid-based Assays Toward Detection of Somatic Mosaicism Christopher S Hong, Chunzhang Yang, Zhengping Zhuang Molecular Therapy - Nucleic Acids.2016; 5: e314. CrossRef
Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR‐tyrosine kinase inhibitor treatment response Ha Young Park, Hyung Joo Oh, Ki‐Hyun Kim, Tae‐Ok Kim, Cheol‐Kyu Park, Hong‐Jun Shin, Jung‐Hwan Lim, Yong‐Soo Kwon, In‐Jae Oh, Yu‐Il Kim, Sung‐Chul Lim, Young‐Chul Kim, Yoo‐Duk Choi Thoracic Cancer.2016; 7(6): 639. CrossRef
Association between GWAS-identified lung adenocarcinoma susceptibility loci andEGFRmutations in never-smoking Asian women, and comparison with findings from Western populations Wei Jie Seow, Keitaro Matsuo, Chao Agnes Hsiung, Kouya Shiraishi, Minsun Song, Hee Nam Kim, Maria Pik Wong, Yun-Chul Hong, H. Dean Hosgood, Zhaoming Wang, I-Shou Chang, Jiu-Cun Wang, Nilanjan Chatterjee, Margaret Tucker, Hu Wei, Tetsuya Mitsudomi, Wei Zhe Human Molecular Genetics.2016; : ddw414. CrossRef